The project aims to develop and commercialize a specific bioprinting platform, including bioinks, software and hardware specialized for printing of human cancer tumors. The European Commission will fund the project with €2.5 million.
”We are incredibly grateful for the EU funding that contributes to the continued development of new technologies in Europe and we look forward to create value for our current and future customers in the pharmaceutical industry, but most importantly, creating patient benefit worldwide,” says Erik Gatenholm, CEO, CELLINK.
The project spans over 29 months and is coordinated and run solely by CELLINK. The goal with the project is to offer a high throughput screening platform for pharmaceutical companies, which enables them to study cell reaction within cancer tumors when exposed to different compounds. CELLINK has retrieved an LOI from a global pharmaceutical company who will help with the validation of the platform. If the project is successful, it will generate income to CELLINK through sales of Bioinks, software and systems.
The total project budget is €3.5 million, CELLINK will fund €1.0 million and the European Commission €2.5 million.
CELLINK is one of our exciting companies in the Biotech Center and is part of the GU Ventures incubator.
For more information, please contact Erik Gatenholm, CEO.
Tel. +46 73 267 00 00 or e-mail: email@example.com